Loading the company…
Loading the company…
In the last ten years FDA made 41 decisions for Dexcom (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2018 (9). The latest was on 2026-06-08.
| Family | Decisions on record |
|---|---|
| CGM & insulin pump management | 142 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-06-08 | 510(k) | K261402 | Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System |
| 2026-02-03 | 510(k) | K253737 | Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System |
| 2025-12-17 | 510(k) | K253710 | Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System |
| 2025-04-09 | 510(k) | K243214 |
In 2025, Dexcom reported engagement with 29,734 surgeons and other clinicians in the states MedaRep covers, worth $3.0M in consulting, speaking, meals and travel for its device products, the most in Texas ($423K to 3,911). Royalties are left out.
| Dexcom G7 15 Day Continuous Glucose Monitoring System |
| 2024-04-23 | 510(k) | K240902 | Dexcom G7 Continuous Glucose Monitoring System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Dexcom.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Texas ($423K, 3,911 engaged), California ($303K, 2,388 engaged), Florida ($215K, 2,403 engaged), Maryland ($164K, 667 engaged), New York ($151K, 948 engaged).